“I think sexual health is at the intersection of mind/body & relationship factors. When sexual health is disrupted, it’s really important to figure out all the pieces…often folks only hear bits and pieces like “use lube” or “use it or lose it” & “we need a holistic approach!” Dr. Sharon L. Bober,...Read More
Colorectal cancer Posts on Medivizor
In a nutshell This study compared the effectiveness of open surgery (OS) and robotic surgery (RS) in patients with rectal cancer. Researchers suggested that RS and OS provided similar treatment outcomes in these patients. Some background Colorectal cancer is one of the most common cancer worldwide. Rectal cancer makes up for one-third of these cases....Read More
How long should patients with locally advanced rectal cancer wait between chemoradiotherapy and surgery to achieve the best outcome?
In a nutshell This study evaluated the timing between chemoradiotherapy (CRT) and surgery in patients with locally advanced rectal cancer (LARC). The study found that patients who had surgery more than 10 weeks after CRT had the best outcome. Some background Rectal cancer is commonly treated with surgery to remove the tumor. LARC is...Read More
Evaluating the effectiveness and safety of stereotactic ablative body radiotherapy in advanced cancer
In a nutshell This study investigated the effectiveness and safety of stereotactic ablative radiation therapy (SABR) in the treatment of patients with oligometastatic (few metastases) cancer. The data showed that the use of SABR in these patients was associated with high overall survival and low toxicity. Some background Oligometastatic cancer (OMC)...Read More
Evaluating the use of radiotherapy followed by chemotherapy before surgery for locally-advanced rectal cancer.
In a nutshell This trial looked at the use of short-course radiotherapy (RT) followed by chemotherapy (CT) and delayed surgery to reduce distant metastases (tumor spread) in patients with locally advanced rectal cancer (LARC). The trial found that this treatment was more effective in controlling distant metastases when compared to standard...Read More
What is the optimal duration of chemotherapy after surgery for patients with stage III colon cancer?
In a nutshell This trial looked at the length of adjuvant chemotherapy (AC; chemotherapy after surgery) for patients with stage III colon cancer. The authors found that 3 months of AC resulted in similar survival with reduced levels of toxicity, and cost compared to 6 months. Some background AC has been standard care for patients with...Read More
Can SOX and mFOLFOX6 chemotherapies be given without radiotherapy before surgery for advanced rectal cancer?
In a nutshell This study evaluated the safety and effectiveness of two chemotherapy regimens (SOX and mFOLFOX6) before surgery for rectal cancer (RC) without radiotherapy. The study found that both regimens were safe and effective in these patients. Some background RC is commonly treated with surgery to remove the tumor. Patients with...Read More
In a nutshell This study evaluated reasons for a delay to ileostomy closure in patients who underwent anterior resection for rectal cancer. This study showed that factors such as having chemotherapy or cancer progression may delay ileostomy closure. Some background The go-to surgical treatment for cancer of the middle and lower rectum involves...Read More
FOLFOXIRI-bevacizumab or FOLFOX-panitumumab for the treatment of left-sided metastatic colorectal cancer without RAS/BRAF mutations.
In a nutshell This study compared the use of chemotherapy and bevacizumab (Avastin) or panitumumab (Vectibix) for the treatment of left-sided metastatic colorectal cancer (mCRC) without BRAF/RAS mutations (permanent changes in genes). The study found that both treatment options are effective for these patients. Some background Patients who...Read More
Bevacizumab combined with first-line chemotherapy for metastatic colorectal cancer in a real-world setting
In a nutshell This article looked at the effectiveness of bevacizumab (Avastin) with chemotherapy for metastatic colorectal cancer (mCRC) in a real-world setting. The authors found that the addition of bevacizumab to chemotherapy regimens provides survival benefits in patients who cannot undergo curative local treatment. Some background...Read More
In a nutshell This study compared the use of pembrolizumab (Keytruda) to chemotherapy for the treatment of patients with colorectal cancer (CRC) and high microsatellite instability (MI). This study showed that patients who received pembrolizumab had a better outcome than those who were given chemotherapy. Some background Patients who are...Read More
In a nutshell This study compared the effectiveness of regorafenib (Stivarga), trifluridine/tipiracil (TFTP; Lonsurf), and combinations of these drugs in the treatment of patients with inoperable colorectal cancer. Researchers suggested that a combination of TFTP and regorafenib is associated with longer survival and fewer side effects. Some...Read More